Skip to content

Category: Biotechnology

De Motu Cordis (DMC) Applauds ARS Pharma’s FDA Approval of Neffy®, Expanding Patient Options to Needle-Free Epinephrine Delivery and Inspiring Confidence in Our Own Development Efforts

By API User

Brisbane, QLD – 16 August 2024 – De Motu Cordis (DMC) is pleased to acknowledge and enthusiastically commends the recent U.S. FDA approval of ARS Pharma’s Neffy®, the first-ever needle-free intranasal epinephrine delivery device for the treatment of anaphylaxis. This groundbreaking approval, announced on August 9, represents a significant step forward in expanding emergency treatment … Continued

SPONTAN® Prescribed to First Patients Under the TGA Authorised Prescriber Scheme

By API User

Sydney, Australia – 16 August 2024 | LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”) is pleased to announce another milestone in introducing SPONTAN®, its innovative nasal spray treatment for Erectile Dysfunction (ED), to the market. SPONTAN® has now been prescribed to its first patients under the Therapeutic Goods Administration’s (TGA) Authorised Prescriber … Continued

LTR Pharma (ASX:LTP) Secures Global Co-Development Agreement with Aptar Pharma for SPONTAN® Nasal Spray

By API User

Sydney, Australia – 13 August 2024 | LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”) is pleased to announce that it has entered into a significant Co-Development Agreement (the “Agreement”) with Aptar Pharma, a global leader in drug delivery systems. This Agreement to collaborate is aimed at accelerating the commercialisation of LTR Pharma’s … Continued

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

By API User

Operational complementarities expected to yield annual synergies of approximately $100 million Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform Combined business positioned to leverage latest advances in the life sciences and technology to deliver … Continued

SPONTAN® Prescribed by Brisbane Men’s Health Expert Under TGA’s Special Access Scheme

By API User

Sydney, Australia – 8 August 2024 | LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”) is pleased to announce that SPONTAN®, its innovative nasal spray treatment for Erectile Dysfunction (ED), has been prescribed by a second men’s health expert in Australia under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). This milestone … Continued

La Trobe finalist in NASA Deep Space Food competition

By API User

La Trobe University and Gaia Project Australia have been named finalists in NASA’s Deep Space Food Challenge for a project designed to grow food for long space journeys such as the Artemis missions to the moon and Mars. The team created a vertical farm where leafy and micro greens are grown in a controlled environment … Continued

How supercharged silk could help heal the heart

By API User

Engineers at UNSW have weaved their magic to create a new material made of silk that could ultimately help regenerate heart tissue. They have taken silk from a domestic silk moth, turned it into a form of jelly called a microgel using light and shown in mice that it is tolerated in the body and … Continued

BlinkLab Limited (ASX:BB1) Partners with Monash University for Study on the Pharmacology of Human Decision-Making

By API User

Sydney, Australia – 6 August 2024 | BlinkLab Limited (ASX: BB1) (“BlinkLab” or “the Company”) is pleased to announce its new collaboration with Monash University to conduct a study on the pharmacology of human decision-making.  The pioneering study aims to explore how ketamine impacts human cognitive processes, providing insights that could revolutionise the treatment of … Continued

LTR Pharma’s SPONTAN® Prescribed to First Patient Under TGA Special Access Scheme

By API User

Sydney, Australia – 5 August 2024 | LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that its innovative nasal spray treatment for Erectile Dysfunction (ED), named SPONTAN®, has been prescribed to the first patients under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). This milestone represents a significant step … Continued

Australian researchers develop a donor stem cell therapy for the successful treatment of osteoarthritis

By API User

New research by Australian biotechnology company Magellan Stem Cells has demonstrated potential for significant therapeutic benefits of an off-the-shelf donor stem cell therapy for Osteoarthritis. The Phase I/II clinical trial assessed the safety and efficacy of MAG200, Magellan Stem Cells’ off-the-shelf allogeneic (donor) stem cell therapy for osteoarthritis of the knee. “Our research indicates that … Continued